Altre lingue Shanghai Junshi Biosciences Co., Ltd.

Azioni

1877

CNE100003FF7

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:20 26/04/2024			Variaz. 5gg	Var. 1 gen.
10,74 ^HKD	+4,88%		+16,23%	-44,75%

25/04	Shanghai Junshi Biosciences riceve l'approvazione di Hong Kong per il farmaco antitumorale toripalimab	MT
24/04	Shanghai Junshi Biosciences Co., Ltd. riceve un avviso dall'Ufficio Farmaci, Dipartimento della Salute, del Governo della Regione di Amministrazione Speciale di Hong Kong	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	25/04
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab	25/04
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	24/04
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	24/04
Junshi Biosciences Gets Nod to Register Toripalimab Injection	08/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	03/04
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	02/04
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	02/04
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	29/03
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	29/03
Junshi Bio's 2023 Loss Widens, Misses Estimates	26/02
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Junshi Biosciences Proposes Share Buyback	02/02
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority	02/02
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	01/02
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	01/02
Shanghai Junshi Biosciences to Narrow Losses	31/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Shanghai Junshi Biosciences Co., Ltd.

Azioni

1877

CNE100003FF7

Altre lingue

Filtri